Positives

• In one documented case, a Long COVID patient saw “marked improvement in functional status and all clinical symptoms” one week after starting baricitinib, including major reductions in joint and chest pain that allowed her to taper off corticosteroids and antianginal medications Gavin Publishers.
  
  

Negatives

• Patients tracking baricitinib case reports report mixed outcomes — some have gone into remission while others felt worse on the drug or saw no improvement Phoenix Rising.
• Even in the two published Long COVID case reports where baricitinib helped angina and joint pain initially, one patient’s improvement was temporary and they relapsed, and Healthline catalogs serious-infection warnings (TB, shingles, fungal infections) that have caused other Long COVID patients to back off Healthline.

Hurdles & Side Effects

• Patients prescribed baricitinib are screened and monitored for serious infections (TB, shingles, fungal), blood clots, malignancy, and elevated lipids; many Long COVID patients balk at the boxed-warning lab schedule and infection vigilance the labelling requires Healthline.
• Outside an active trial, off-label baricitinib for Long COVID is essentially impossible to access in the US because of cost (>$2,500/month) and prescriber reluctance without a rheumatologic indication VUMC News.